首页>投融资
QurAlis
B轮
QurAlis Corp operates as a biotechnology company. The Company discovers, develops, and commercializes new therapies for the treatment of motor neuron diseases such as amyotrophic lateral sclerosis.In December 2018, a medical deveice company had been spun-out from a parent company QurAlis Corp.In March 2023, QurAlis Corp closed an oversubscribed $88 million Series B financing, bringing the total financing to $143.5 million.In May 2020, the company announced series A financing to raise US $42 million bringing the total funding US $50.5 million to date.In November 2018, the company announced the raising of a seed extension, bringing the total funding to date to $5.5 million. In addition, the company had won a Pfizer-sponsored Golden Ticket, and became a resident company of Johnson & Johnson Innovation, JLABS (JLABS)
基本信息
-
公司全称QurAlis Corp
-
类型肌萎缩侧索硬化症新疗法研发商
-
产业领域药品研发/制造
-
公司人数15~50人
-
地址100 Cambridge Park Drive CAMBRIDGE MASSACHUSETTS 02140; US; Telephone: +17818167031;
-
联系电话(1)781.816.7031
-
邮箱info@quralis.com(+1) 781.816.7031
-
成立时间2016-12-12
投融资
-
2023-03-09B轮8800万美元DROIAAmgen VenturesALS Investment FundSanford BiosciencesLSP Dementia FundDementia Discovery FundMission BioCapitalPolaris PartnersEQT Partners杜比创投Mission Bay CapitalMitsui & Co. Global InvestmentINKEF Capital赛诺菲MP Healthcare Venture Management
-
2020-05-13A轮4200万美元DROIAAmgen VenturesSanford BiosciencesPolaris Partners杜比创投Mitsui & Co. Global InvestmentMP Healthcare Venture Management
-
2018-11-19种子轮550万美元Amgen VenturesMission BioCapitalBioInnovation capitalMP Healthcare Venture Management
-
2018-04-05种子轮未透露Alexandria Venture InvestmentsAmgen VenturesMP Healthcare Venture Management
- 加载更多
相关投融资企业
PreA轮
Epitopea Ltd develops cancer immunotherapies intended to offer therapeutics targeting a novel class of tumour-specific antigen. The company's technology platform builds on our proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens (aeTSA), known as CryptigenTM TSAs, curing cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication.In May 2022, Novateur Ventures had participated in the $13.6M (£10.3M) seed investment raised by Epitopea Ltd.In April 2022, Epitopea had announced a $13.6M seed investment from Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital and Fonds de solidarité FTQ
C轮
Alpha-9 Oncology 是一家处于临床阶段的放射性药物公司，致力于开发差异化和高度靶向性的放射性药物，有望显著改善癌症患者的治疗。Alpha-9 运用专有技术和深厚的基础专业知识，走在定制放射性药物工程的前沿，这些药物经过优化，可选择性地向肿瘤部位输送射线，同时最大限度地减少脱靶效应。Alpha-9 正在推进一个强大的新型放射性药物管线，该管线采用系统化的分子设计方法，具有向多个有效肿瘤靶点扩展的广泛潜力。
A轮
March Biosciences是一家临床阶段生物技术公司。该公司致力于治疗对现有免疫疗法无反应的挑战性癌症。其主要资产MB-105是一种以CD5为靶点的嵌合抗原受体T细胞（“CAR-T”）疗法，CD5是一个在正常和恶性T细胞（包括T细胞相关的白血病和淋巴瘤）中广泛表达的蛋白质。这限制了其作为癌症治疗靶点的用途，因为正常免疫系统功能所需的健康T细胞将与恶性T细胞一起被破坏。MB-105经过特别设计，既能保留健康的T细胞，又能保持对CD5阳性肿瘤细胞的杀伤力。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息